INTRODUCTION
Diabetes mellitus (DM) is characterized by chronic hyperglycemia due to insulin deficiency in the case of type 1 diabetes or insulin resistance in the case of type 2 diabetes. It is projected that there are more than 150 million in the world [1] . As many as 80% with noninsulin dependent DM have cystopathy, which is characterized by impaired sensations of bladder fullness, in-
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Int Neurourol J June 30, 2019 creased bladder capacity, decreased bladder contractility, and elevated postvoid residual urine volume [2, 3] . Moreover, functional and morphological manifestations of diabetic bladder dysfunction (DBD) in studies of streptozotocin (STZ)-induced DM animal model are time-dependent [4] . Bladder hypertrophy and remodeling, increased contractility and associated neurogenic changes occur soon after the onset of DM [5, 6] , while decreased peak voiding pressure in the cystometric measure develops only at a later stage of DM [4, 7] . However, compared with this well documented DBD, little is known about the effects of DM on urethral function.
Previous animal studies have demonstrated that DM could also damage the innervation of the urethra and directly impairs urethral striated and smooth muscles [8, 9] . The resulting diabetic urethral dysfunction (DUD) could degrade voiding function by impairing outlet function and urethra-to-bladder reflexes [10] . DM induce an impairment of coordinated micturition consisting of external urethra sphincter (EUS) phasic activity and urethra smooth muscle (USM) relaxation mechanisms, resulting in detrusor-sphincter dyssynergia (DSD), which is an involuntary contraction of the EUS during detrusor contraction [11, 12] . However, the time-dependent functional and morphological changes in DUD have not been well characterized, and the alterations of neurotransmitter systems and urethra-to-bladder reflexes have not been well clarified.
Our main purpose is therefore to review the previous literatures regarding time-dependent changes of urethral function in DM and explore an early intervention target to prevent the urethral dysfunction to the progression of DM-induced damage to the lower urinary tract (LUT).
EPIDEMIOLOGICAL STUDY
In 2015, the International Diabetes Federation (IDF) estimated that approximately 415 million adults aged 20-79 years (about 8.8%) had DM worldwide and that the condition accounted for 12% of global healthcare expenditure. The IDF predicts that, if current trends continue, by 2040 one in 10 adults will have DM [10] . More than 29 million people in the United States (US) have DM and 86 million of US adults have prediabetic conditions including metabolic syndrome, according to the Centers for Disease Control and Prevention National Diabetes Fact Sheet. During recent decades, rapid economic development and urbanization have also increased the prevalence of DM in Asia. For example, China has the highest diabetes prevalence worldwide, with more than 98 million people being affected. The prevalence of DM has increased significantly in recent decades and is now reaching epidemic proportions in China [13, 14] . Furthermore, it is worth mentioning that the number is projected to rise to nearly 143 million by 2035 [15] . Although different sampling methods, screening procedures, and diagnostic criteria were used, these data document a rapid increase in DM.
Macrovascular and microvascular complications of DM, including cardiovascular diseases, retinopathy, nephropathy, and neuropathy, have been well investigated [16, 17] . DM also contributes to the earlier onset and increased severity of urologic conditions, leading to debilitating urologic complications, including LUT dysfunction [12, 18] . LUT complications are found in more than 80% of individuals diagnosed with DM, a higher rate than that of widely recognized complications such as neuropathy and nephropathy, which affect less than 60% and 50%, respectively [19] Although the most common, bothersome LUT complication of DM is DBD, DUD can also cause LUT dysfunction and the effects of DUD should be given attention.
PRECLINICAL STUDY

Functional changes of the urethra in DUD
Studies of the effects of DM on LUT function have largely focused on the bladder. As noted, the bladder is only one important component of LUT. The urethra, which serves as the bladder outlet, must remain closed during storage to maintain continence and open to provide a low resistance outlet during voiding. Thus, any dysfunction of urethral closing or opening adversely affects continence or voiding function, respectively, and it must be considered when assessing the effects of DM on LUT function.
STZ-treated DM rats have been extensively used as a rodent model of the voiding dysfunction encountered in DM patients. In this model, there are time-dependent morphological and functional changes in myogenic and neurogenic components of the bladder and urethra that affect both voiding and storage phases [4, 20, 21] . DM may initially promote urethral dysfunction characterized by increased urethral pressure during micturition. Urethral pressure showed a significant increase in 5-week STZ-induced DM rats, and this may be attributed to the impairment of the USM relaxation mechanism because administration of L-arginine, the substrate of nitric oxide (NO), can significantly partially restore the urethral relaxation and im-prove voiding efficiency by [8] .
It is noted that elevation of urethral pressure during the micturition reflex can increase the bladder outlet resistance, and the bladder detrusor tries to compensate to maintain efficient voiding by increasing the duration of bladder contraction. The peak contraction amplitude also increased in cystometrogram measurements, and EUS-electromyogram (EMG) recordings showed increased frequency of EUS-EMG bursting discharge during voiding in 6-week DM rats [22] . DSD also occurred in approximately 30% of the 5 and 10 weeks STZ-induced DM rats, which suggested that DM could lead to EUS dysfunction, decreased USM relaxation with reduced NO responsiveness, and increased urethral smooth muscle responsiveness to α1-adrenergic stimulation [12] . Interestingly, the insensitivity to NO responsiveness and hypersensitivity to α1-adrenergic agonists were more common in 10-week DM rats, suggesting that urethropathy is evident in both short-term and long-term STZ induced DM rats [12] .
Few studies have investigated longer-term alterations in the urethra secondary to DM. In a previous study, DM changed the EUS-EMG pattern in a different manner at 6 and 20 weeks after STZ induction [22] . The differences in EUS-EMG patterns between 6-and 20-week diabetic rats might be caused by different mechanisms. Early changes in micturition function in DM may be attributable to functional adaptation to an increase in bladder work and overdistention arising from hyperglycemia-induced diuresis [5, 23] . However, diabetic neuropathy may play an important role in inducing LUT changes in late stages of DM [3] . Furthermore, the decreased voiding efficiency can be attributable to chronic hyperglycemia, which induces a decompensated, hypertrophied detrusor muscle. DM-induced neuropathy may also contribute to the decompensated bladder whose contraction is inadequate to expel the increased bladder capacity since it has been reported that DM cystopathy is associated with polyneuropathy affecting autonomic nerve fiber [3] . Taken together, potential mechanisms inducing early-and latephases of DUD are summarized in Fig. 1 , mainly based on previous preclinical study data.
Morphological changes of the urethra in DUD
To better understand the mechanistic nature of DM urethropathy, we must understand the function of the normal urethra [10, [24] [25] [26] . In this regard, the urethra is composed of 3 muscle layers, including the proximal USM-Longitudinal (USM-L), which is the innermost and extends into the bladder base, the USM-Circumferential (USM-C), which has its greatest thickness at the mid urethra, and the striated EUS, which is also circular in orientation and surrounds the distal urethra. While EUS relaxation is passive due to cessation of its excitation, the opening of the urethral smooth muscle conduit is not a passive event but rather requires active USM-L contraction (mediated by acetylcholine [Ach] and/or prostaglandin E2 [27, 28] ) and active USM-C relaxation (mediated by NO [29] ). Urethral closure clearly depends on active USM-C contraction (mediated by norepinephrine [NE] through α-adrenergic receptors) and may or may not rely on active mechanisms in terms of USM-L relaxation.
Previous studies reported that the morphology of the urethra can also be altered in DM. For example, the urethras from 6 weeks and 20 weeks in alloxan-induced diabetic rats had greater values of total thickness than did the control rats whereas the urethra from 6-and 20-week DM rats had reduced thickness of the urothelium of the urethra [30] . In 6-and 20-week STZ-induced DM rats, the morphological images revealed that the striated muscle bundles in 20-week diabetic rats were atrophied compared with those of controls although no obvious changes were observed in the thickness of EUS of 6-week diabetic rats compared with controls ( Fig. 1) [22] .
Few studies have investigated the longer-term morphological alterations in the urethra secondary to DM. A higher total thickness and muscle layer thickness and higher connective tissue and collagen content were observed in the urethras in 44-week alloxan-induced DM rats. However, no changes in the collagen type III/I ratio were found in the urethra between DM rats and age-matched normal rats [31] . Notably, some researchers have reported that either long-term mild hyperglycemia or short-term severe hyperglycemia have detrimental impacts on muscle health. They are both involved in the failure to maintain healthy skeletal muscle that may contribute to the development of pelvic floor dysfunctions via different pathways [32] .
The changes of neurotransmitter and growth factor mechanisms in DUD
The 2 main functions of the LUT, and the storage and periodic expulsion of urine, are dependent on the coordinated activity of the urinary bladder and urethra [33, 34] . Voiding is accomplished by the activation of the parasympathetic efferent neurons which release ACh to contract the bladder smooth muscle and NO to relax the USM. Simultaneously, the excitatory input to EUS from spinal motor neurons is inhibited to allow urine flow. Storage of urine involves tonic activation of the sympathetic system, which releases NE. NE acts on beta adrenergic receptors (β-ARs) to relax the bladder smooth muscle and on α1-adrenergic receptors (α1-ARs) to contract the USM. In addition, the excitatory motor input to the EUS is turned on to maintain continence, especially when stress is applied to the bladder.
Nerve growth factor (NGF) also plays an important role in the growth, survival and development of sympathetic and sensory peripheral neurons. Moreover, rats with STZ-induced DM showed a significant, time-dependent decrease in NGF levels in the bladder and L6 to S1 dorsal root ganglia [35] . Therefore, we reviewed the time-dependent changes of the neurotransmitters and its corresponding receptors in DUD.
Nitric oxide
NO is synthesized by a family of enzymes known as nitric oxide synthase (NOS). Three distinct isoforms of NOS, namely endothelial NOS (eNOS), neuronal NOS (nNOS), and inducible NOS (iNOS), have been described, based on the cells in which they were first identified, isolated, purified, and cloned [36] . nNOS is specifically expressed in neurons of the nervous system, which cause the generation of nNOS-derived NO [37] . nNOS-derived NO exhibits modulatory effects on parasympathetic nerves, which mainly act as a crucial effect on urethral relaxation during micturition reflex [38] .
NO is thought to play a role in peripheral neurotransmission, and it is believed to be an important neurotransmitter in nonadrenergic, noncholinergic (NANC) nerves of the peripheral nervous system. Evidence that NO is a neurotransmitter in NANC nerve-mediated smooth muscle relaxation comes from studies of the rat anococcygeus muscle in which the NOS inhibitor L-NMMA abolishes nerve-mediated relaxation; this response is reversed by L-arginine [39] . Abnormalities in the NOmediating mechanisms in the cavernosal, gastric, duodenum, and anococcygeus smooth muscle have been identified in DM. Since NO plays an important role in modulating bladder neck and USM tone, it is clearly of interest to investigate its role in the pathogenesis of the urethral dysfunction associated with DM.
NO can diffuse into the smooth musculature of the urethra, in which it stimulates the synthesis of cyclic guanosine monophosphate (cGMP) and finally induces smooth muscle cell relaxation [40] . L-arginine therapy, which could augment urethral smooth muscle relaxation by increasing NO production, may be useful for partially restoring the urethral relaxation mechanism due to increased formation of NO mediated cyclic GMP formation in the urethra in 5-week STZ-induced diabetic rats [8] . Moreover, a recent study showed that DM induced elevation of urethral pressure and dysfunction of urethral relaxation in 8-week STZ-induced DM rats, and grape seed proanthocyanidin extract alleviated urethral dysfunction through modulating the NO-cGMP pathway [41] . Furthermore, DUD decreased urethral smooth muscle relaxation and NO responsiveness in 5-and 10-week STZ-induced DM rats, suggesting that DUD is time-dependent, and early intervention targeting bladder outlet resistance may be indicated for the therapy of DMinduced LUT dysfunction [12] .
Norepinephrine
Sympathetic postganglionic terminals, which release NE, elicit contractions of the bladder base and USM, and it has been reported that the relaxation of the bladder body mediated mainly though β3-ARs. Moreover, selective β3-AR agonists effectively relaxes human detrusor muscle [42] , indicating that the most important β-AR for bladder relaxation is the β3-AR, at least in humans. However, in urethral and prostatic smooth muscle, sympathetic excitation is mediated by an α1-AR subtype to induce contractions [43] . Furthermore, sphincter function is also modulated by the spinal noradrenergic pathways, and NE-induced increase in excitability of urethral rhabdosphincter motoneurons in the spinal cord may be partially through α1-ARdependent depolarization in rats [44] .
According to a previous study, the relaxation mechanisms of urethral striated and smooth muscles during the micturition reflex were impaired in diabetic rats, but inhibition of α1-ARs could decrease the lowest urethral pressure (urethral perfusion pressure [UPP] nadir) and UPP fluctuation, suggesting that α1-ARs are a potential intervention target for urethral dysfunction in DM [9] . Moreover, DUD could increase responsiveness to α1-adrenergic agonists in both 5-and 10-week STZ-induced DM rats [12] . Thus, it is assumed that early inhibition of α1-ARs may be useful to improve DUD.
In addition, UPP nadir during urethral relaxation was significantly smaller in 8-week diabetic rats, while intravenous administration of tamsulosin, an α1-AR antagonist, significantly decreased the UPP nadir and baseline UPP. Therefore, it is assumed that the upregulation of the α1A-and α1B-ARs in the urethras may be a contributing factor to DUD [45] although the exact mechanism of α1-AR involved in DUD need be further explored.
Nerve growth factor NGF is a protein with tropism for effector tissues and their innervations [46, 47] . NGF plays an important role in the growth, survival and development of sympathetic and sensory peripheral neurons [48, 49] . In the urinary tract, NGF is produced in smooth muscle cells and urothelial cells of the bladder. In the urothelium, it can trigger changes in afferent fibers, either by reducing or increasing their excitability [50] . NGF induces the uptake of calcium ions which, besides releasing catecholamines, are important in maintaining smooth muscle tonus of the urethra [51] .
Previous studies have also revealed that deficient retrograde axonal transport of NGF from target organs to sensory pathways may be involved in diabetic neuropathy [52, 53] . It has been showed that down-regulated NGF expression in the urinary bladder of DM rats leads to decreased NGF transport to its afferent pathways, which contributes to diabetic cystopathy [54] . Rats with STZ-induced DM showed a significant time-dependent decrease in NGF levels in the bladder and L6 to S1 dorsal root ganglia that was associated with voiding dysfunction attributable to defects in A-and C-fiber bladder afferents [35] . However, urine NGF level was increased, and this may be due to inflammation and apoptosis in the bladder, which could cause the loss of NGF binding receptors and increased expulsion of NGF in bladder [55] . Thus, it is possible that increased urine NGF may affect the urethral function. Furthermore, a previous study revealed that the expression of NGF and p75 neurotrophin receptor level were significantly decreased in the urethras from the 8-week diabetic rats [45] . However, further studies are needed to explore whether a time-dependent decrease of urethral NGF levels is observed and involved in DUD.
Taken together, the above-mentioned neurotransmitters and its corresponding receptors undergo time-dependent changes to induce DUD (Fig. 1) ; however, the changes of other neurotransmitters or growth factors, such as ACh, brain-derived neurotrophic factor and serotonin have not been established. Further studies are needed to clarify these points.
The changes of urethra-to-bladder reflexes in DUD
Abundant evidence demonstrated that the sensory input generated in the urethra has a relevant impact on bladder activity [34, 56] . Urethral anesthesia prevented normal bladder emptying of healthy subjects [57] , which suggests that changes in urethro-vesical crosstalk can occur in DM and should be given attention. Several studies have demonstrated DM-induced damage to bladder afferent neurons, with A-and C-fiber afferent neurons being injured and the responses to chemical stimulation with capsaicin and acetic acid being reduced [35, 58] , therefore, similar damage to urethral afferent neurons would be expected.
In 10-week STZ-induced DM rats, chemical stimulation of urethral afferent neurons with capsaicin or dilute acetic acid showed that urethral afferent neuronal function was altered. Moreover, DM affected urethral afferent neurons differentially, compromising those expressing TRPV1 receptors. Low-frequency oscillations of USM are known to be neurogenically mediated and can increase EUS activity, revealing the existence of a hitherto undescribed reflex pathway: a smooth-to-striated muscle urethra-to-urethral reflex. Furthermore, in 9-and 12-week STZ-induced DM rats, nitrergic relaxations and adrenergic-induced contractions in the isolated diabetic rat urethra display similar properties to controls, suggesting no dysfunction on the nitrergic or α1-AR function in the smooth muscle. This further implies that compromised urethral relaxation and increased adrenergic agonist sensitivity observed in vivo in this model may be due to the disruption of neural signaling between the urethra and the spinal cord, or within the central nervous system (CNS) [59] . Thus, DM-induced alterations in urethra-innervating neuronal pathways should be further clarified in future studies.
CLINICAL STUDY
Diabetic neuropathy has been reported in approximately 8% patients at the diagnosis of DM. However, electrophysiologic evidence of neuropathy can be demonstrated in most patients after 5-10 years of DM [60] . Although abnormal function of bladder afferent pathways is viewed as a key clinical manifestation in DBD [21] . Moreover, positive afferent feedback from the urethra may also be compromised by diabetic neuropathy in DM rats [61] . However, the clinical evidences related to abnormal function of urethral afferent pathways in DM have not been established.
Abundant evidences showed the abnormal function of urethra efferent pathways is related to diabetic neuropathy. An earlier investigation including a series of 30 male diabetics found that fifty percent of the patients had large areflexic bladders, and increased duration of the motor unit potentials (MUP) in the periurethral striated sphincter, the striated anal sphincter, and the levator ani [62] . Diabetic vesicourethral dysfunction is highly correlated with decreased motor nerve conduction velocity in the tibial nerves, which is indicative of DM induced somatic neuropathy [63] . Diabetic polyneuropathy affects the pudendal nerve, as detected by external anal sphincter-EMG recordings, which showed an increase in MUP mean duration, mean amplitude, mean phases, satellite rate, and in percentage of long duration MUPs and polyphasic potentials [64] .
In addition, DM has traditionally been handled as a peripheral metabolic disease. However, more recently, noninvasive brain imaging techniques providing information on brain anatomy and function have indicated structural and functional abnormalities associated with DM. Functional MRI studies have also shown that the hypothalamus is more sensitive to glucose concentration changes in patients with type 1 diabetes than in nondiabetic controls [65] . Since hypothalamus is closely related to micturition, modulation of central autonomic circuitry including the hypothalamus represents a potential therapeutic target for managing glucose metabolism and LUT function in diabetic patients although further studies are needed to explore CNS pathophysiology in DM-induced LUT dysfunction.
CONCLUSIONS
DM can induce the time-dependent impairment of urethral function, which can significantly contribute to DM-induced LUT dysfunction and symptoms. The underlying mechanisms are multifactorial, including time-dependent functional and morphological changes in the urethra, and the alterations of neurotransmitter systems and urethra-to-bladder reflexes. However, compared with the previous studies on DM-induced bladder dysfunction, the research on DUD is much limited. Further understandings of the molecular and functional mechanisms of DUD will be mandated to identify potential targets for therapeutic intervention of DM-related LUT dysfunction including DUD.
